A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

2025-524282-24-00 · tracked via the Priya Life Science EU tracker

Sponsor

Neurocrine Biosciences Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Hormonal diseases

Decision date

23/07/2026

Enrollment target

Sites

Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain

Condition studied

Classic Congenital Adrenal Hyperplasia (CAH)

Investigational medicinal product(s)

NBI-74788

Eligibility

Age group

18-64 years

Sex

Female, Male

Primary endpoint

Change from baseline in pre-GC serum androstenedione at Week 24.

Endpoint detail

Not applicable

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524282-24-00 on CTIS ↗ ← All trials in the EU